Endovascular Engineering (E2) has secured an oversubscribed $80 million Series C financing co-led by Gilde Healthcare and Norwest. This capital infusion will fund the commercial launch of its Hēlo® Thrombectomy Platform. The device is designed to treat pulmonary embolism, a leading cause of cardiovascular death.
Advancing Treatment for Pulmonary Embolism
The Hēlo® platform is engineered to overcome the limitations of legacy thrombectomy systems for venous thromboembolism (VTE). It utilizes a patented dual-action mechanism that combines mechanical clot disruption with powerful aspiration. This innovative design aims to provide a more effective and efficient solution for removing dangerous blood clots.
A key feature is its ability to deliver large-bore performance through a small-profile catheter, enabling efficient single-pass procedures. This approach is designed to enhance procedural efficiency and improve clinical outcomes for patients. The platform's launch aligns with the growing adoption of mechanical thrombectomy as a preferred VTE treatment.
Strategic Vision and Leadership
Dan Rose, CEO at E2, called the financing a pivotal milestone in the company's mission to improve VTE treatment options. He confirmed the funds will be used to build a strong commercial organization. The investment also supports continued advancements in research, development, and operational capabilities to meet demand.
As part of the financing, E2 will welcome two new members to its board of directors. Geoff Pardo of Gilde Healthcare and Dr. Zack Scott of Norwest will provide strategic oversight. Their extensive experience in medical technology will be invaluable as E2 enters its commercial growth phase.
Investor Confidence and Market Potential
Gilde Healthcare's investment signals strong conviction in E2's approach, with Geoff Pardo highlighting its potential to define a new clinical care category. This marks Gilde's return to the VTE space after its successful investment in Inari Medical. The firm believes the Hēlo® Platform addresses significant unmet needs in thrombectomy.
Dr. Zack Scott of Norwest emphasized the serious nature of pulmonary embolism and the need for more effective solutions. He expressed confidence in E2's leadership and their strategy for building a scalable commercial organization. Norwest anticipates the technology will become a leading platform for mechanical thrombectomy treatments.
The oversubscribed round drew participation from a broad syndicate of investors, reflecting widespread market confidence. Existing backers like Santé Ventures, 415 Capital, and Panakès Partners reaffirmed their support. The round also attracted a new global strategic investor, further validating the company's technology and strategy.
Academic Roots and Innovation Pathway
The core innovation behind the Hēlo® platform originated from research conducted at the University of Michigan. The project was nurtured through a collaborative ecosystem involving the university's engineering and innovation partnership programs. This academic foundation provided the fertile ground necessary for developing the breakthrough technology.
Early support from investors like the Michigan Biomedical Venture Fund was crucial in the technology's initial development. Company founder Luis Savastano has credited the university's unique culture of innovation as a key factor in its success. This journey from academic research to a commercial product highlights a successful technology transfer model.
This $80 million financing marks a transformative moment for Endovascular Engineering, positioning it for a successful commercial launch. With an advanced platform, robust financial backing, and experienced leadership, E2 is well-equipped to impact pulmonary embolism treatment. The company is now poised to set a new standard in the VTE intervention market.